ZURICH (Reuters) - Roche Holding AG's Herceptin combined with pertuzumab showed "impressive results" in a phase II breast cancer trial, the Swiss drugmaker said on Friday.
The company also cited a late-stage trial showing that Herceptin treatment prevented disease progression in women with aggressive metastatic breast cancer.
In the trial, women with breast cancer received either Herceptin -- which is also known as trastuzumab -- with Xeloda, another Roche drug, or Xeloda alone.
The data are due to be presented at an American Society of Clinical Oncology (ASCO) meeting.
